The PRWIRE Press Releases https:// 2019-01-16T23:26:45Z Avaya Announces Enhancements to its Avaya Desktop Experience 2019-01-16T23:26:45Z avaya-announces-enhancements-to-its-avaya-desktop-experience SANTA CLARA, Calif. – January 15, 2019 – Avaya Holdings Corp. (NYSE:AVYA) today announced enhancements to its Avaya Desktop Experience portfolio of smart business devices, including a new line of professional-grade communication headsets, expanded Broadsoft UC feature support, enhancements to its Essential Experience J100 Series, and the availability of Device Enrollment Service 2.0. The new portfolio of L100 series professional grade headsets initially includes five corded headsets, with cordless headsets available in the near future. These headsets enable unique AcousticEdge™ technology to provide the maximum audio experience while protecting employees from long-term headset usage issues. These headsets are engineered to work particularly for Contact Center agents, with an innovative, quick disconnect option and supervisor listen-in capabilities. See these headsets in action here. Building on the November 2018 expansion of its Open SIP smart devices portfolio, Avaya has significantly increased the ability of the Essential Experience J100 Series of smart business desktop devices to support Broadsoft UC features, enabling UCaaS service providers to add Avaya Open SIP to their UCaaS offerings on a broad scale. Additionally, Avaya introduced a new full color, high resolution Essential Experience J100 Expansion Module that can be attached to Essential Experience J169 or J179 IP Phones to provide an expanded display. This module can be used for administration and reception positions to view the status of lines being monitored and supports Avaya SIP, H.323, and Open SIP architectures. Avaya also announced that the Essential Experience J179 now supports Bluetooth connectivity. Also introduced is a new 2.0 version of Avaya’s Device Enrollment Service (DES), which facilitates zero-touch provisioning for smart desktop device installation. New capabilities include support of the G14 languages, re-enrollment support, notification and data export enhancements, and security enhancements. Avaya’s DES has been specifically designed to reduce deployment cost and help large service providers scale their cloud business faster. "Avaya continues to make significant strides in revolutionizing the desktop space and advancing the Open SIP market,” said Ard Verboon, General Manager of the Devices portfolio, Avaya. “With the availability of support for Broadsoft advanced features combined with the large breadth of the Avaya Desktop Experience portfolio, Avaya is now a one-stop shop for any smart device that a company may need, and UCaaS providers can now look to Avaya to meet their smart devices needs–from the professional desktop, to campus mobility, to personal and room conferencing, to headsets–as well as industry vertical solutions.” Additional Resources · On January 17th at 10:00am PST, join Alaa Saayed, Frost & Sullivan ICT Industry Director & Fellow and Karen Hong, Avaya Senior Product Manager, Devices as they discuss the Open SIP devices market, ecosystem, and opportunities for UCaaS Service Providers in 2019. · See the Essential Experience J100 series portfolio in action. · Download more information about Avaya’s Open SIP portfolio. About Avaya Businesses are built on the experiences they provide, and every day millions of those experiences are built by Avaya (NYSE: AVYA). For over one hundred years, we’ve enabled organizations around the globe to win – by creating intelligent communications experiences for customers and employees. Avaya builds open, converged and innovative solutions to enhance and simplify communications and collaboration – in the cloud, on-premise or a hybrid of both. To grow your business, we’re committed to innovation, partnership, and a relentless focus on what’s next. We’re the technology company you trust to help you deliver Experiences that Matter. Visit us at www.avaya.com. Cautionary Note Regarding Forward-Looking Statements This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to expected feature releases and statements about future products, expected cash savings and statements about growth, exchange listing and improved operational metrics. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Registration Statement on Form 10 filed with the Securities and Exchange Commission, may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Company’s filings with the SEC that are available atwww.sec.gov. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, considering these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Source: Avaya Newsroom Avaya A.I.Connect Ecosystem Expands with New Partners and Offers 2019-01-16T22:48:42Z avaya-a-i-connect-ecosystem-expands-with-new-partners-and-offers Santa Clara, Calif. – January 16, 2019 – Avaya Holdings Corp. (NYSE: AVYA) today announced further expansion of its unique A.I.Connect ecosystem with new partners and partner offers, including an increased focus on incorporating new Artificial Intelligence (AI) capabilities into its Unified Communications (UC) solutions. Knowmail and over.ai are the newly designated A.I.Connect partners with solutions aligned to Avaya’s overall UC and collaboration strategies. They join the broader Avaya ecosystem of companies collaborating on the use of AI and machine learning technologies for Unified Communications and Contact Center, including Verint, with whom Avaya recently expanded its partnership inclusive of additional AI-powered and Cloud solutions. Avaya’s vision for AI in Unified Communications includes strengthening workforce productivity in four key ways: Effortless Prioritization – enabling employees to deal with massive amounts of content such as email, IM, messages, and calls by intelligently prioritizing and responding to the most pressing items first. Smart Communications – leveraging presence to enable “best choice first” and anticipating optimal channels for communications with peers and workgroups Streamlined Interactions – offering timely suggestions and voice activation of communication services, simplifying manual or point-and-click interfaces required by many different communications channel choices today. Optimized Decisions – Providing personalized visibility to complete, relevant data sets that is all too often lost from view or difficult to find. “Avaya’s deep expertise in creating communications and collaboration experiences for enterprise workers leverages AI capabilities for natural language understanding and personal assistants. With the addition of new AI solutions from companies like Knowmail, over.ai and others, our A.I.Connect initiative continues to expand the ecosystem helping to provide optimal AI capabilities for strengthening workforce engagement across omnichannel communications,” said Eric Rossman, Avaya Vice President, Alliances and Partnerships. “Avaya continues to aggressively position AI as a critical element of both the UC and Contact Center strategies offered to their clients,” said Zeus Kerravala, Principal Analyst at ZK Research. “Building off the long-standing success of their DevConnect Program, Avaya’s A.I.Connect initiative allows them to capitalize upon the expertise of their ecosystem for a wide range of use cases, helping enterprises establish early leadership positions through the application of analytical and predictive capabilities enabled by AI and Machine Learning capabilities.” Founded in 2014 with the mission to liberate employees from the agony of information overload, Knowmail supports effortless prioritization by providing a highly secure, personalized AI email productivity capability to Avaya’s Unified Communications clients, offering the user a choice of visual, voice, or mixed experiences. “We’re excited to be part of Avaya’s A.I.Connect ecosystem, and to bring the power of personalized communications to the Avaya customer base,” said Haim Senior, CEO of Knowmail. “Through our relationship, Knowmail and Avaya are capable of delivering a wholly new productivity experience, offering email prioritization by urgency, along with predicted next-best-actions to increase focus, quickly get things done, save time, and stay organized, all within the Avaya Vantage desktop smart phone. This allows professionals more focus and flexibility in their workday, completing urgent tasks even before they can boot and login to their computer in the morning.” over.ai is an AI-enabled voice platform that tackles complex tasks by embracing natural language processing technology and allowing end users to engage naturally, to create a fundamental shift in human-computer interactions. Evolving from point-and-click to listen-and-enable interactions, over.ai will bring voice-enabled AI that streamlines communications tasks on Avaya platforms through listening, understanding and learning from its own environment in real-time. “Enabling organizations to enhance their user experience across every channel will have an enormous impact on productivity and communication,” said Noam Fine, over.ai CEO. “We’re excited to be able to link over.ai’s Voice AI Cognitive Services with Avaya solutions and make this a reality.” In addition, Avaya continues to deepen its overall AI and Cloud strategy for the contact center with an expanded resale agreement with existing A.I.Connect partner Verint. Through this broader arrangement, Avaya customers are now able to obtain powerful AI-enabled solutions that deliver actionable insights across text and speech channels, plus key knowledge management, feedback and online community capabilities directly through Avaya and authorized Avaya channel partners. About A.I. Connect A.I. Connect is a consortium of companies dedicated to supporting and promoting the interoperability and value of artificial intelligence and machine learning within enterprise communications. Established by Avaya in 2017, the initiative creates a community of technology firms who can collaborate on creating the broadest set of technology options of AI capabilities for Avaya customers worldwide to deliver more engaging experiences to their own employees and end customers. More information on A.I.Connect can be found at www.avaya.com/aiconnect. Technology firms interested in joining the A.I.Connect ecosystem can request consideration through aiconnect@avaya.com. About Avaya Businesses are built on the experiences they provide, and every day millions of those experiences are built by Avaya (NYSE:AVYA). For over one hundred years, we’ve enabled organizations around the globe to win – by creating intelligent communications experiences for customers and employees. Avaya builds open, converged and innovative solutions to enhance and simplify communications and collaboration – in the cloud, on-premise or a hybrid of both. To grow your business, we’re committed to innovation, partnership, and a relentless focus on what’s next. We’re the technology company you trust to help you deliver Experiences that Matter. Visit us at www.avaya.com. Cautionary Note Regarding Forward-Looking Statements This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to, expected feature releases, statements about future products, expected cash savings and statements about growth, exchange listing and improved operational metrics. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Registration Statement on Form 10 filed with the Securities and Exchange Commission, may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Company’s filings with the SEC that are available at www.sec.gov. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Source: Avaya Newsroom ### Growth and inclusivity drive Avaya’s channel strategy for 2019 2018-12-05T05:09:41Z growth-and-inclusivity-drive-avayas-channel-strategy-for-2019 Dubai, United Arab Emirates – December 5, 2018 – Avaya Holdings Corp. (NYSE:AVYA) today announced new measures aimed at enabling channel partner growth. The announcements were made at the Avaya Partner Summit 2019 in Dubai, where the company is hosting the EMEA and APAC regions’ leading channel heavyweights, market movers and technical and sales leaders. The new measures, which come as an update to the Avaya Edge partner program, will provide a path for channel partners to move from one value proposition to more advanced ones – moving to solution selling; and from solution selling to innovation building; and from innovation building to enabling true business transformation. The updates to Avaya Edge also place an emphasis on partner inclusivity, aiming to enable growth regardless of the size or business model of the channel partner. This means that Avaya Edge is now the only channel program in the world to provide equal growth opportunities to partners of any size. “Our own growth is inexorably linked to the growth of our partners, regardless of where they sit today on the Avaya Edge Program. Our growth strategies need to align with those of our partners if we’re to succeed in our goals,” said Fadi Moubarak, Vice President – Channels, Avaya International. “Avaya wants its channel partners to continue growing – pure and simple. As a result, in 2019, we’ll be focusing our efforts on three key areas to enable that. There will be a bigger emphasis on cloud; we will enable the delivery of complete solutions that build on our market-leading, API-driven ecosystem; and we will deliver new technologies and innovations that offer answers to genuine business challenges.” With the Edge Program, Avaya has already made significant progress in growing partner business over the past year. Between 2017 and 2018, the number of partners eligible for rebates increased by 281%, and there was a 159% increase in the number of partners who had seen more than 10% growth. The company’s strategy for 2019 will be to build on these positive results. Much of the coming year’s focus will be on empowering channel partners to more easily roll out cloud-based products as cloud adoption continues to skyrocket. With offerings for both the mid-market and the enterprise, Avaya’s range of cloud-based services continues to expand, and is expected to provide significant growth opportunities for both large and small channel partners in 2019. Avaya is also leveraging its market-leading, open standards-based communications platforms to encourage and empower channel partners to provide holistic solutions to their customers. Solutions made available through the Avaya DevConnect and Avaya A.I.Connect programs, for example, bring leading technology disruptors with readily integrated technology solutions into Avaya’s channel. Through the programs, these solutions are made available to channel partners, who can use them to propose innovative, vertical-specific technologies for their customers. Alternatively, Avaya’s open ecosystem can be leveraged by channel partners to build their own solutions. With many of Avaya’s most successful partners having built new innovations on top of Avaya’s platforms for their customers, Avaya is rolling out new tools and APIs that enable and encourage channel partners to take the lead on innovation. These solutions, and more, are being demonstrated at the Avaya Partner Summit 2019, taking place in Dubai from December 4 to 5, 2018. From embedding AI and biometrics into communications workflows to creating seamless omni-channel experiences, summit visitors will find real, working solutions to the biggest business challenges that companies face. “It is our role as a technology vendor to provide our partners with opportunities to continue growing and transforming as the market shifts. Our aim with this event is to continue in our efforts to help empower our channel partners, enabling them to realize even greater levels of growth with Avaya,” added Moubarak. ## About Avaya Businesses are built on the experiences they provide, and every day millions of those experiences are built by Avaya (NYSE: AVYA). For over one hundred years, we’ve enabled organizations around the globe to win – by creating intelligent communications experiences for customers and employees. Avaya builds open, converged and innovative solutions to enhance and simplify communications and collaboration – in the cloud, on-premise or a hybrid of both. To grow your business, we’re committed to innovation, partnership, and a relentless focus on what’s next. We’re the technology company you trust to help you deliver Experiences that Matter. Visit us at www.avaya.com. Cautionary Note Regarding Forward-Looking Statements This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," “our vision,” "plan," "potential," "preliminary," "predict," "should," "will," or “would” or the negative thereof or other variations thereof or comparable terminology and include, but are not limited to, expected cash savings and statements about growth, exchange listing and improved operational metrics. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Registration Statement on Form 10 filed with the Securities and Exchange Commission, may cause its actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. For a further list and description of such risks and uncertainties, please refer to the Company’s filings with the SEC that are available at www.sec.gov. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, considering these risks and uncertainties, the matters referred to in the forward-looking statements contained in this report may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Source: Avaya Newsroom All trademarks identified by ®, TM, or SM are registered marks, trademarks, and service marks, respectively, of Avaya Inc. All other trademarks are the property of their respective owners Seagate Launches New Data-Readiness Index Revealing Impact Across Four Global Industries As 30 Percent Of Data Forecasted To Be Real-Time By 2025 2018-11-27T05:15:21Z seagate-launches-new-data-readiness-index-revealing-impact-across-four-global-industries-as-30-percent-of-data-forecasted-to-be-real-time-by-2025 SYDNEY, Australia – 27 November, 2018 – The global datasphere1 could grow to 175 zettabytes by 2025, and industries such as Financial Services, Manufacturing, Healthcare, and Media and Entertainment are helping to define this new era of data growth. This is according to an IDC White Paper The Digitization of the World – From Edge to Core, sponsored by global data and storage leader Seagate Technology, which examines impending shifts to the global data model. While Healthcare currently has the smallest share of the global enterprise datasphere among key industries examined in the study, it is primed to grow the fastest, far surpassing the Media and Entertainment sector and matching the Financial Services sector by 2025. The growth reflects advancements in healthcare analytics and imaging technology, as well as the increasing amount of real-time data created in medical care. The study, The Digitization of the World – From Edge to Core, assesses data-readiness of the four critical industries that encompass nearly half of the global enterprise datasphere. It does so by using DATCON (DATa readiness CONdition), an index that evaluates management, usage and monetisation of data to help inform today’s business leaders on their level of data-readiness. Ranging from 1 (Critical) to 5 (Optimised), DATCON scores are calculated across a number of metrics, including data growth, criticality, security, investment, management, skills and C-level involvement. DATCON: evaluating global data readiness by sector Industries are in various states of readiness and should take action to prepare for, and capitalise on, data growth. Using the DATCON index, the study identifies the most pressing initiatives businesses must consider as they approach 2025: Manufacturing and Financial Services scored the best overall at 3.3 each, representing the greatest use of edge computing in the four industries, with opportunity for blockchain, analytics and AI. Despite its rapid growth, at 2.4, healthcare has room for improvement as well in data readiness. Survey results indicate blockchain will be important for the industry, but nearly 60 percent lack a strategy or have yet to implement any initiative. Media and Entertainment received the lowest DATCON score of 2.0, showing the sector ripe for advanced data technologies; particularly in data security and data management. “We are at the beginning of an era where both data creation and data utilisation are forecasted to grow rapidly over the next decade. While some industries are more prepared for digital transformation than others, all businesses need to be ready to act on a solid digital strategy in order to be successful in the data age,” said Dave Mosley, Seagate’s chief executive officer. “Data technologies are becoming central for productivity expansion, data monetisation and value-creation. We are excited to be part of this transformation and be a strong supporter to enable these opportunities for the years to come.” Enterprise out in front The enterprise is fast becoming the world’s primary data steward in today’s connected world. The Digitization of the World study predicts that the installed bytes across the enterprise is to represent over 80 percent of total installed bytes worldwide in 2025. This trend will only continue to amplify the data protection responsibilities of companies around the world. The cloud is the new core Also revealed by The Digitization of the World study, almost half (49%) of the world’s stored data could reside in public cloud environments by 2025. The shift to the public cloud is largely being driven by a world filled with IoT sensors that are constantly capturing, recording, and analysing data in business environments. With businesses looking to centralise data management and delivery, there is an increased reliance on the connectivity, performance and convenience that cloud services provide. As companies continue to pursue the cloud for increasing data processing and storage needs, cloud data centers are becoming the new enterprise data repository. In essence, the cloud is becoming the new core. “While endpoints continue to be the primary location for data creation in the short term, the fastest growth is forecasted to happen at the core and the edge - with more data stored in the core than in the world’s endpoints by 2025. This will be particularly true for major industries as edge computing continues to be a key driver of business-critical factors and digital transformation,” said David Reinsel, senior vice president at IDC. For more information on “The Digitization of the World – From Edge to Core” and DATCON index, download the study: www.DataAge2025.com. About Seagate Seagate creates space for the human experience by innovating how data is stored, shared and used. Learn more at www.seagate.com. Follow Seagate on Twitter, Facebook, LinkedIn, Spiceworks, YouTube and subscribe to our blog. © 2018 Seagate Technology LLC. All rights reserved. Seagate, Seagate Technology and the Spiral logo are registered trademarks of Seagate Technology LLC in the United States and/or other countries. All other trademarks or registered trademarks are the property of their respective owners. Seagate reserves the right to change, without notice, product offerings or specifications. 1 The global datasphere is the quantification of the amount of data created, captured, and replicated across the world. # # # Media Contact Richelle Gillett Einsteinz Communications Email: richelle@einsteinz.com.au Ph: +61 02 8905 0995 Breaking the Chain of Infection with GloveOn Protect 2018-11-26T06:32:18Z breaking-the-chain-of-infection-with-gloveon-protect Sydney, Australia, November 21st, 2018 – Mun Australia announced today the launch of their first antimicrobial glove, GloveOn® Protect, to join their expanding glove range. “There is no greater accomplishment for us, than the introduction of the world’s first non-leaching antimicrobial glove. We are humbled to bring this into the Australian healthcare sector, and continue on this journey together for better infection prevention,” said David Teng, Director of Mun (Australia) Pty Ltd. The most compelling feature of the antimicrobial glove is the highly advanced photosensitiser dye, which is bound to the glove’s outer surface and is the key component in helping reduce healthcare-acquired infections (HAIs). Photosensitisers generate singlet oxygen upon exposure to light and attack the microbe’s proteins and lipids, resulting in the destruction of harmful bacteria, such as MRSA and VRE. Transmission of microbes from the patient’s environment to a healthcare worker’s glove is therefore reduced, helping break the chain of infection. Studies show that using this non-selective method to kill bacteria will unlikely result in the development of resistance. GloveOn Protect has been created in collaboration with Chemical Intelligence UK. Rob Gros, Chief Executive Officer of Chemical Intelligence UK, drew inspiration for creating the technology following the swine flu pandemic in 2010. “This exciting innovation has been made possible through our partnership with Hartalega [Mun Australia’s parent company]. I am excited to see the global impact that singlet oxygen technology will make in reducing HAIs,” said Rob Gros. GloveOnProtect adds to the multi-modal approach for combating HAIs and preventing contamination and transmission of pathogens from healthcare workers hands to patients. The antimicrobial properties of GloveOn Protect have been proven to kill up to 99.999% of microbes, and has shown to be easy to use, non-toxic, non-irritant, and non-sensitising on skin, and is the next game-changing healthcare innovation for infections.   About Mun With head offices located in Australia, The United States, Malaysia, China and India, Mun is dedicated to produce the best quality gloves across the globe and become the leader for premium healthcare products that enhance peoples’ care, wellbeing and welfare around the world. Every GloveOn® product is created with superior precision, reliability, integrity and quality. Our gloves exceed numerous international standards, including AS/NZS, ASTM, EN and ISO, and are TGA compliant. For more information on Mun, visit the company’s website at https://munglobal.com.au Infinite Care trailblazes new generation of aged care innovation 2018-11-16T02:53:01Z infinite-care-trailblazes-new-generation-of-aged-care-innovation BRISBANE, 16 November 2018 -- Infinite Care has become the first aged care provider to implement TechnologyOne and Telstra Health’s integrated aged care solution, aligning with its vision to be an Australian leader and innovator of residential aged care.   TechnologyOne and Telstra Health have worked collaboratively to provide the complete, end-to-end solution for residential aged care providers.   As one of Australia’s fastest-growing residential aged care providers, Infinite Care’s Director of People & Corporate Services, Rebecca Pacey, said the organisation selected TechnologyOne and Telstra Health’s solution due to their collaborative partnership and significant experience in the aged care sector.   “We had a level of comfort because of the successful implementation and relationship we had previously with Telstra Health with their Clinical, Care and Medication Management solution. With TechnologyOne working closely to understand our business requirements, and the level of communication between all three parties, it has enabled a successful integration,” said Pacey.   The solution integrates the resident administration and Medicare claiming capabilities of Telstra Health’s Resident Manager software, with the financial capabilities of TechnologyOne’s OneAgedCare solution, to offer a seamless aged care solution.   “Like many organisations, we wanted to minimise the number of systems and solutions we use,” Pacey said. “We were looking for a solution that gave us the ability to scale information management and reporting, as well as provide efficiencies from combining our multiple solutions into one.”   The implementation across all of Infinite Care’s sites will allow it to automate a number of back office functions, reducing the time taken to prepare and submit information to Medicare. With an end-to-end solution, the flow of data between Resident Manager and TechnologyOne reduces the need for double handling and ensures information is up-to-date and timely for business reporting.   Resident Manager’s real-time integration with Medicare helps to reduce the double entry of information into the Medicare portal.   “We've now got this nice workflow happening across the business, from when a resident first enquires with us, right through to all of our resident billing and financial reporting. We now have greater assurance that our billing is timely and our reporting streamlined. The integration with Medicare has helped to speed up the process of getting information or feedback from Medicare.”   TechnologyOne Chief Operating Officer Stuart MacDonald said TechnologyOne was proud to be partnering with Telstra Health to deliver a new generation of aged care software.   “Our partnership with Telstra Health aligns with our strategy to continuously deepen and broaden our enterprise solutions for the industries we operate in,” MacDonald said. “This new partnership puts our enterprise solution far ahead of the market, making us the only enterprise solution provider with the depth and breadth that we offer.”   MacDonald added: “Infinite Care has benefited from our collective industry expertise and capability, enabling it to integrate disparate systems into a single solution that is both scalable and compliant.”   Telstra Health’s Head of Aged, Disability & Community Care, Michael Donnelly, stated that Telstra Health is excited about the opportunities the partnership with TechnologyOne will provide for aged care providers.   “In partnering with TechnologyOne, our clients benefit from working with two client-focused, Australia based organisations, with long-term proven solutions,” Donnelly said.   “Telstra Health is committed to continuous investment in the aged care sector, and Resident Manager is just one of the ways we support aged care providers. Our market-leading Clinical, Care and Medication Management solution combined with Resident Manager and TechnologyOne offer an end-to-end seamless experience for residential aged care providers.”   - Ends -   About TechnologyOne TechnologyOne (ASX:TNE) is Australia's largest enterprise software company and one of Australia's top 200 ASX-listed companies, with offices across six countries. We create solutions that transform business and make life simple for our customers. We do this by providing powerful, deeply integrated enterprise software that is incredibly easy to use. Over 1,200 leading corporations, government departments and statutory authorities are powered by our software. We participate in only eight key markets: government, local government, financial services, education, health and community services, asset intensive industries, project intensive industries and corporates. For these markets we develop, market, sell, implement, support and run our preconfigured solutions, which reduce time, cost and risk for our customers. For more than 30 years, we have been providing our customers enterprise software that evolves and adapts to new and emerging technologies, allowing them to focus on their business and not technology. Today, our software is available on the TechnologyOne Cloud and across smart mobile devices. For further information please visit TechnologyOneCorp.com   About Telstra HealthTelstra Health is the largest Australian-based provider of software for healthcare providers and funders. Our vision is to be the leading provider of digital health solutions that shape a connected future for healthcare. We provide software applications, open platforms and services to the pharmacy, hospital, primary, diagnostic, Indigenous health and aged, disability and community care sectors in Australia, as well as Government and insurance companies. Telstra Health’s aged, disability and community care software solutions span across the spectrum of care, from workforce management and rostering solutions for in-home and community care, to resident, medication and clinical management software for residential aged care providers. Telstra Health is a subsidiary of Telstra Corporation, Australia’s leading telecommunications company. For further information please visit www.telstrahealth.com Rimini Street Expands Investment and Operations in Asia-Pacific 2018-11-16T00:48:31Z rimini-street-expands-investment-and-operations-in-asia-pacific AUCKLAND, NEW ZEALAND, November 16, 2018 – Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that it has expanded its operations in the Asia-Pacific region with the launch of its new subsidiary, Rimini Street New Zealand Limited, and the opening of its new office in Auckland to address the growing demand for Rimini Street’s premium, ultra-responsive support services in New Zealand. Rimini Street’s expansion was announced at a gala event held at The Northern Club in Auckland, where clients, local IT leaders and the special guest of honor, Ambassador Scott P. Brown, the U.S. Ambassador to New Zealand, were hosted by Rimini Street’s general manager for Asia-Pacific, Andrew Powell, and Rimini Street corporate senior executives. Growing demand for IT optimisation and a business-driven IT roadmap Rimini Street launched its new subsidiary in response to the region’s increasing desire for software support solutions that can help optimise their IT spend and enable them to liberate significant funding for their business transformation initiatives. Rimini Street already supports nearly 50 clients with operations in New Zealand, including local brands James Pascoe, Spark, 2Degrees Mobile, Refining New Zealand and The University of Auckland. By switching to Rimini Street support from the vendor’s support, organisations have saved up to 90 percent of the total cost of maintenance of their SAP and Oracle software assets and are able to run their current ERP releases with no forced upgrades for a minimum of 15 years from the date they switched support. Rimini Street clients also benefit from the Company’s flexible, premium-level enterprise software support model, including its industry-leading Service Level Agreement (SLA) of 15-minute response times for critical Priority 1 cases. In addition, each client is assigned a Primary Support Engineer (PSE) with an average of 15 years’ experience in their particular enterprise software system, backed by a broader team of technical experts. By switching their support to Rimini Street, organisations are able to take back control of their IT roadmaps with a ”business-driven roadmap” strategy that provides much more flexibility and value compared to the vendor roadmap, allowing CIOs to focus on creating value and providing competitive advantage for growth. “Organisations in New Zealand, both public and private, spend hundreds of millions of dollars every year on their annual enterprise software support and maintenance, yet see little return from this significant spend,” said Andrew Powell, general manager, Asia-Pacific, Rimini Street. “Our conversations with CIOs are squarely focused on how we can help them dramatically lower the total cost of ownership of their stable, mature enterprise systems as part of a hybrid computing model and business-driven roadmap, and as a result, we are experiencing increased demand in the region. With Rimini Street, organisations have the option to break free from the seemingly never-ending upgrade cycle dictated by the vendor’s roadmap – an expensive and disruptive path for companies to undertake just to stay fully supported. With our new operation in Auckland, we are better able to engage with and support organisations in New Zealand who want to significantly cut their software support spend and take back control of their IT roadmaps.” Region at risk of “falling behind” on innovation Recent research from Vanson Bourne, commissioned by Rimini Street, found that enterprises in the ANZ region plan to spend the second-least amount on IT innovation in the world in the next 12 months, and they plan to increase their IT innovation spend by just 6.31% in the 12 months following the survey, well below the global average of 10.94%. “New Zealand is famous for innovation, but it is at risk of falling behind the rest of the world,” continued Powell. “New Zealand CIOs know that it’s important to spend their IT budgets on more than daily operations. With budget pressures between operating costs and the need to invest in innovation, CIOs need to reassess the value of existing support arrangements and explore better software support options designed to provide a greater ROI. Rimini Street enables CIOs in New Zealand to unlock significant savings and redirect that funding into critical innovation initiatives.” To download an eBook summary of the survey, “The State of Innovation: Priorities and Challenges,” click here. About Rimini Street, Inc. Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products. The Company has redefined enterprise software support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, Salesforce, SAP and other enterprise software vendors to save up to 90 percent on total maintenance costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,700 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, third-party support provider. To learn more, please visit http://www.riministreet.com/, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn. (C-RMNI) Forward-Looking Statements Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, continued inclusion in the Russell 2000 Index in the future; changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; the final amount and timing of any refunds from Oracle related to our litigation; our need and ability to raise additional equity or debt financing on favorable terms; the terms and impact of our 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the success of our recently introduced products and services, including Rimini Street Mobility, Rimini Street Analytics, Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on 10-Q filed on November 8, 2018, which disclosures amend and restate the disclosures appearing under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on March 15, 2018, and as updated from time to time by Rimini Street’s future Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication. # # # © 2018 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein. Pharma veterans guide next generation of researchers and entrepreneurs 2018-11-12T22:36:44Z pharma-veterans-guide-next-generation-of-researchers-and-entrepreneurs Pharmaceutical sector leaders and experts joined government and NGO representatives to share their collective wisdom with young researchers, entrepreneurs and industry professionals at The Bridge Program’s Residential Training Program last week. The Bridge Program was launched in 2017 to boost the commercial output of Australian pharmaceutical research by providing face-to-face and online training in research translation and the commercialisation of medicines. Run by Queensland University of Technology, it involves a consortium of 15 pharmaceutical companies, universities and industry associations, and selects 100 participants from across Australia annually. The three-day Residential Training Program, now in its second year, involved workshops, case studies, networking opportunities and presentations from national and international guests, including CEO of Innovation and Science Australia, Charlie Day, Amgen’s VP of Global Health Economics, Martin Zagari, and Member for Bennelong John Alexander MP, to name a few. Mr Zagari presented on the value of medicines in healthcare and society, which he said was being challenged by a shift in focus from value to cost. He said fixating on initial investment costs was misleading, as almost all investments in medicines became cost neutral and most became cost saving, yielding enormous value. “In the US, every dollar spent on medicines for congenital heart failure returned $3-$10 in savings,” he said. “Every 1% reduction in cancer mortality would deliver $500 billion in savings globally. We need to consider what the cost of not improving treatments will be.” Mundipharma’s Director of Corporate Affairs, Meriana Baxter, chaired a session that tasked cross-functional teams with delivering a mock pitch to industry executives role-playing as venture capital investors. The “investors” were impressed with what the teams achieved in a short timeframe, but provided detailed advice on how they could cut through more effectively. My Linh Kha, Executive Director and General Manager of Amgen Australia and New Zealand, spoke of the promise of the medical discoveries that may be made by the attendees, and the benefits they may have on patients in the future. “I am so proud of the collective knowledge and experience that can be leveraged through this program,” Ms Kha said. “I wish an opportunity like this existed when I began my career, and I am sure we’ll be seeing the impact of this effort for years and decades to come.” Mr Alexander closed the program with a reflection on his time representing his electorate and the home of “Pill Hill”. “I’m so lucky to have had the opportunity to meet so many in this industry,” Mr Alexander said. “You are all motivated by the common goal of improving quality of life, extending life and addressing illness.” The program’s final event for 2018 will be held at Queensland University of Technology on 13 December with keynote speaker Professor Ian Frazer, who co-invented the technology enabling human papilloma virus (HPV) vaccines. More information on The Bridge Program can be found here: research.qut.edu.au/bridge/, including a full agenda for the Residential Training Program. The Bridge Program collaborators include Mundipharma, MTPConnect, AbbVie, Amgen, The Australian Private Equity and Venture Capital Association Limited (AVCAL), Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Janssen-Cilag, Macquarie University, Medical Research Commercialisation Fund, Medicines Australia, MSD, Novartis and Pfizer. G MEDICAL PURCHASES TELERHYTHMICS LLC, MEDICAL DIAGNOSTIC MONITORING SERVICE PROVIDER 2018-11-02T02:32:40Z g-medical-purchases-telerhythmics-llc-medical-diagnostic-monitoring-service-provider Expands infrastructure to increase nationwide footprint and services for remote vital signs monitoring healthcare services in the USA Provides additional capacity, access to technologies and payer network November 2, 2018 - Sydney, Australia – Mobile and e-Health company G Medical Innovations Holdings Ltd (G Medical or the Company) (ASX: GMV) is pleased to announce that its wholly owned Delaware incorporated subsidiary, G Medical Innovations USA Inc, has executed an agreement to acquire 100% of the outstanding membership interest of Telerhythmics LLC (Telerhythmics) (a Tennessee limited liability company), a US based cardiac diagnostic monitoring services provider. Telerhythmics, based outside Memphis, Tennessee, is a 24-hour cardiac diagnostic monitoring service used by hospitals and physician offices, and provides its monitoring services throughout the eastern region of the U.S. G Medical will acquire all the outstanding membership interests of Telerhythmics from NASDAQ listed imaging technologies company Digirad Corp (NASDAQ: DRAD) for a total up front consideration of US$1,950,000, subject to working capital adjustments. Completion of the agreement remains subject to the satisfaction of certain customary conditions precedent, including the receipt of any necessary consents from third parties including but not limited to government authorities. Telerhythmics, LLC., booked historical revenue from 1 January 2018 to 30 September 2018 of ~US$3.174M1 . The Telerhythmics acquisition, in addition to the Company’s acquisition of Cardiostaff Diagnostic Services Inc (as announced on 30 October 2017) will create a sizable player in the cardiac diagnostic US monitoring space, and in addition, provide G Medical with a solid base of business across the Southeast and Southwest territories. Telerhythmics is a Medicare and Medicaid designated IDTF (Independent Diagnostic Testing Facility) that provides physician practices and hospitals with arrhythmia monitoring services including mobile cardiac telemetry ("MCT"), cardiac event monitoring, Holter monitoring, and pacemaker analysis. The Telerhythmics acquisition will substantially increase insurance coverage and create a distinct competitive advantage, providing G Medical with ~100 commercial payor agreements across local, regional and national markets and an additional 30-35M covered lives (individuals insured); with the Company’s aggregated sum increasing to ~100M+ covered lives when considering existing G Medical Diagnostic Services payor agreements. Via the acquisition, G Medical will also gain access to several large health systems including Baptist, Ochsner, and HCA, and also to existing agreements in place with large insurance providers such as Blue Cross Blue Shield (BCBS), which has current reimbursement status for MCT (auto detect auto send) monitoring device. Further, Page 2 of 3 the Company’s regulatory approved medical devices will be translated to existing customers of both Telerhythmics and G Medical, providing for a superior technology offering and monitoring services when compared to traditional Holter monitoring. Telerhythmics, LLC., was established in 1996. It has long been recognized for superior clinical patient monitoring given its foundation of employing experienced critical care nurses. Telerhythmics’ business is synergistic and complementary to G Medical’s existing infrastructure and operations following the Company’s successful acquisition and integration of CardioStaff, and further increases the Company’s nationwide footprint and services for remote vital signs monitoring healthcare services across the US. Commenting on the latest acquisition, G Medical CEO Dr. Yacov Geva, said: “Acquiring Telerhythmics further strengthens our Company’s US footprint as we further focus our efforts to become a leader in complete (endto-end) and comprehensive vital signs medical monitoring and cardiac diagnostic services across the US. Telerhythmics brings additional payer contracts, clinical and commercial scalability, access to current monitoring technologies and an existing platform to launch our proprietary medical devices with the aim to further grow our market share in this important area of digital health delivery.” Cardiac diagnostic monitoring and remote vital signs monitoring healthcare services is a rapidly growing industry in the US and the Company is well positioned to become an emerging leader in the E-Health and Vital Signs Monitoring space. The Company continues its preparations towards the submission of its F-1 Registration Statement towards a Dual-Listing on the NASDAQ Stock Exchange, where a number of the Company’s peers are currently listed. About G Medical Products G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals. The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members. G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings. - Ends - Contact: Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Tel: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com WHO ARE PROPEL FUNERAL PARTNERS? 2018-11-01T03:34:31Z who-are-propel-funeral-partners The funeral industry in Australia is currently estimated to be $1.1 billion and provides essential services to individuals and families dealing with, or preparing for, death and bereavement. However, navigating the funeral industry when someone has died can leave many of us vulnerable to upselling and confused with no understanding of the industry and little idea of our funeral rights and choices. In Australia there are two main listed players, being InvoCare Limited (ASX: IVC)and the newer Propel Funeral Partners Ltd (ASX: PFP). Between them they likely account for more than 40% of the Australian market after recent acquisitions. The following information is provided in a series of articles to assist consumers learn more about some of the largest funeral companies in Australia. In this article we provide an overview of Propel Funeral Partners. About Propel Funeral Partners? Propel Funeral Partners was established in FY12 and is now the second largest private provider of death care services in Australia and New Zealand. Propel was founded and is managed by Propel Investments Pty Ltd. The company listed on the Australian Stock Exchange in late November 2017 as it sought to emulate InvoCare by buying up smaller family owned funeral homes. They own funeral homes, cemeteries, crematoria and related assets in Queensland, New South Wales, Victoria, Tasmania, South Australia, Western Australia and New Zealand. Propel performed over 10,000 funeral services in FY18 and the Company’s portfolio currently comprises 108 locations (54 freehold and 54 leasehold) in Australia and New Zealand, including 24 cremation facilities and 7 cemeteries. It’s recent acquisitions include Seasons Funeral Homes in Western Australia and Norwood Park in New South Wales, Newhaven Funerals in Queensland. Which funeral homes are owned by Propel Funeral Partners? Corporate versus Independent Funeral Directors Although most consumers will pick a funeral home brand based on expensive marketing campaigns, it pays to shop around. We wouldn’t consider buying a car or paying for a wedding without learning everything we can about the product or service. The same decision making process should also apply to funerals! Choosing between a corporate or family-owned funeral home is a personal question. Corporate funeral homes are often able to charge a premium due to brand recognition and the belief that their services will be of a higher professional quality. On the other hand, independent funeral homes in Australia work for consumers and not shareholders of publicly listed companies, InvoCare and Propel Funeral Partners. They are often more connected with the communities they serve and have more freedom to tailor funerals to reflect the wishes of the family (rather than being bound by strict package options). GRAVE CONCERNS HELD FOR FUNERAL CONSUMERS EZIFUNERALS CALLS ON CONSUMERS AND FAMILY OWNED FUNERAL HOMES TO CHALLENGE THE FUNERAL DUOPOLY Make the Independent Funeral Choice the Right Choice If local ownership and community involvement are important to you, you should ask who owns and operates the funeral home you are considering. By choosing to use the services of an independent funeral director, listed with eziFunerals, you are selecting the help of a trusted professional – who can help you anywhere, anytime. They are not distracted or bound by corporate rules handed down from head office and shareholders but can be flexible and responsive to individual needs, providing a highly personal and compassionate service. So make the right choice and get value for money by selecting an Australian, independent and family owned funeral director to conduct a funeral. For more information on funeral costs in each of the states, see our city specific pages: Funeral Directors Sydney Funeral Directors Melbourne Funeral Directors Brisbane Funeral Directors Adelaide Funeral Directors Perth Funeral Directors Hobart About eziFunerals eziFunerals is a free consumer advocacy and funeral planning platform that supports individuals and families cope with end of life decisions, death and funerals. We are an independent, Australian-owned and operated company, and are not a subsidiary of any other corporation. We are not part of any other funeral company. Founded by consumers frustrated by how difficult it was to get independent information, eziFunerals supports consumers plan a funeral, compare prices and select the right funeral director anywhere, anytime. ‘Tis the season! Remove allergens, pet hair, bad odours and germs 2018-10-31T01:10:22Z tis-the-season-remove-allergens-pet-hair-bad-odours-and-germs With nearly 1 in 5 Australians suffering allergic rhinitis (hay fever) and the sale of hay fever medicines doubling1 as a result, it’s good to know that an air purifier can trap 99.97% of allergens down to 0.3 microns in size. Simply using an air purifier could help reduce the need for expensive and invasive medicines such as nasal sprays and oral antihistamines, and they can be used in the home, at the office and even in vehicles. Hay fever does occur throughout the year but peaks in October and November. ACT has the highest rate of allergic rhinitis (26%), followed by Tasmania (23%), South Australia, Victoria and Western Australia (all 21%), and NSW (19%). The lowest rates were in NT (12%) and Qld (17%). Unlike many health conditions, allergic rhinitis is most common in the middle years of life: 15 to 59 years and is triggered by an allergic reaction. Common triggers include house dust, animal fur, pollens, fungal spores and air pollutants. The highest standard of air purifiers use HEPA filters, which stands for High Efficiency Particulate Air, and designates that the filters are able to trap 99.97% of particles that are 0.3 microns or larger. One of Australia’s largest suppliers of portable air purifiers is Andatech with its Ionmax products that range from a personal unit that can be used in cars, trucks and on aeroplanes, to a larger model, the ION390, which can be placed in open spaces at home and in offices. The unit combines three forms of efficient air purification technologies: HEPA filtration, UV light and negative ions. Five-step filtration process The intelligent Ionmax ION390 UV HEPA Air Purifier utilises a five-step filtration process to completely and efficiently filter and clean indoor air. Starting with the pre-filter, the ION390 removes large airborne articles from the air. The HEPA air purifier filter then removes microscopic particles from the air, while the carbon filter removes undesirable odours and VOCs (Volatile Organic Compounds). The next step is the Titanium Dioxide filter and the UV lamp, which work hand-in-hand to break down harmful contaminants in the air and kill mould, bacteria and viruses. Finally, the ION390 UV HEPA Air Purifier releases negative ions into the air to help revitalise and refresh indoor air. Ionmax air purifiers help to clean and filter the air not only of dust, hair and dander, but also from airborne allergens, bacteria, viruses, odours and harmful chemicals. With added features such as negative ionisers, UVC lamps and improved filters, Ionmax air purifiers ensure clean, healthy air anywhere and anytime. Andatech’s HEPA air purifiers have a large air intake that traps airborne particles at a rate of more than 99%, eliminating many fine particles and allergens from the air. By placing an Ionmax air purifier in the home or workplace, users can enjoy healthier, cleaner air free of pollutants. Portable and stylish, they also operate quietly and their compact design makes them easy to move around different rooms. Ionmax air purifiers are energy efficient and affordably priced so clean and healthy indoor air is accessible to everyone. Jamie, who runs a small business (office) in tandem with a commercial kitchen, said, “I noticed that the kitchen odours were substantially less when leaving the filter running on [the] lowest setting. The staff were unaware I had implemented the filter, but hay fever in the office literally stopped the day I put it in.” Bryan purchased an ION390 from Sleep Solutions and said, “On the first night [after purchasing it and] running the filter for four hours I had one of my best night sleeps in a long time.” https://www.andatech.com.au/air-purifiers/ Ends Further information: 1 https://www.aihw.gov.au/reports/chronic-respiratory-conditions/allergic-rhinitis-hay-fever/contents/allergic-rhinitis-by-the-numbers RRP of ION390 is $369 (HEPA filter) RRP of ION401 is $299 (Ionic tower) RRP of ION330 is $149 (car & desktop model) RRP of ION260 is $69 (personal, wearable with 2 x AA batteries) RRP of ION420 is $299 (HEPA filter) About Andatech: Andatech is a 100% Australian owned company that designs, supplies, supports and services safety and wellness products including high quality alcohol and drug testing equipment, and air quality products. The company has the widest range of Australian Standard-certified breathalysers in Australia, which are designed for personal use, in workplaces, at hospitality venues (wall mounted) and as car interlock devices. Drug testing kits cover saliva and urine testing of 7 drug groups providing error-free results. Air quality products include dehumidifiers, air purifiers, humidifiers and aroma diffusers. https://www.andatech.com.au/ HIGH RES IMAGES CAN BE DOWNLOADED FROM THE WMC PR PRESS OFFICE AT: https://wmcpr.com.au/tis-the-season-remove-allergens-pet-hair-bad-odours-and-germs/ or send an email to Wendy McWilliams at wendy@wmcpr.com.au CE, FDA & CFDA Approval Granted for Guangzhou China Production Facility 2018-10-30T05:04:29Z ce-fda-cfda-approval-granted-for-guangzhou-china-production-facility October 30, 2018 – Sydney, Australia – Mobile and e-Health company G Medical Innovations Holdings Ltd (“G Medical” or the “Company”) (ASX: GMV) is pleased to announce it has successfully completed the independent audit process to achieve CE, FDA and CFDA regulatory approval for the Company’s Production Facility in Guangzhou China. The Company is proud to inform its shareholders that it achieved excellent results during the multistage independent audit process conducted during September and October for all three regulatory bodies (CE, FDA and CFDA). The full audit has now been completed, and the results of the audit are expected to be published and searchable to the public later this week via the following directory; https://www.sgsgroup.com.cn/en/certified-clients-and-products/certified-client-directory The Company expects to receive its final certification documentation from the Regulatory bodies within 3 weeks. This is a significant milestone for the Company which intends to utilise the full production capacity of its Guangzhou facility. As previously announced to the market, the Company has numerous agreements in place globally and the approvals granted for the Guangzhou Facility enables the Company to commence production and distribution to those territories which recognise CE, FDA and CFDA certification and have already granted regulatory approval for the Company’s medical devices. G Medical CEO Dr. Yacov Geva said, “We are very pleased to have achieved CE, FDA and CFDA approval, which exemplifies the high-quality of our Production Facility and our strong in-Country relationships. The Company has been committed to achieving this major milestone in record timeframes and we now look forward to being able to meet the demand from our global partnerships and rapidly execute our commercial plans.” G Medical has a strong pipeline of customer demand and the increased production capacity positions the Company to fulfil its expansion into the rapidly growing E-Health market. As the Company continues its preparations for the listing of its Chinese subsidiary, Guangzhou Yimei Innovative Medical Science and Technology Co. Ltd, on the main board of The Hong Kong Stock Exchange (HKSE), the granting of CE, FDA and CFDA approval was an important achievement in this process. The Company requests that its securities stay in trading halt, pending an announcement in respect of a convertible note capital raising and a material acquisition. The Company requests the trading halt until the market opens on 31 October 2018 or until the announcement is made, whichever is the earlier. Corporate Advisors Otsana Capital 108 Outram Street West Perth WA 6005 Telephone: +61 8 9486 7244 www.otsana.com Investor Relations Viriathus Australia Level 8/525 Flinders Street Melbourne VIC 3000 Telephone: +61 2 8667 5360 www.viriathus.com Media Enquiries Closer Communications David Wolf Tel: + 61 411 111 787 david@closer.com.au About G Medical Innovations G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity. The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories. For more information on G Medical, please visit www.gmedinnovations.com Dr Anh speaks out in response to the media frenzy about the issue of plastic surgeons’ social media being responsible for body image anxiety. 2018-10-25T02:16:42Z dr-anh-speaks-out-in-response-to-the-media-frenzy-about-the-issue-of-plastic-surgeons-social-media-being-responsible-for-body-image-anxiety The solution to low body image issues is quite simple, argues Perth Female Plastic Surgeon, Dr Anh. She writes an open letter in response to the media frenzy about the issue of plastic surgeons’ social media being responsible for body image anxiety. It is disappointing to read the gross generalisations in the articles in the Daily telegraph and the Sydney Morning Herald that suggest that Plastic Surgeons are part of the growing problem of body image anxieties. As a female plastic surgeon in Perth who is active on social media, as a woman who has had her fair share of insecurities about her body, as a mum of 3 children including a 12 year old daughter, I would argue that this is a sweeping generalisation and one I find negative and somewhat insulting to those of us who are against body shaming and passionate about empowering body positivity. To point the finger at social media of plastic surgeons as one cause of a complex problem is I believe oversimplistic and ignoring a much bigger issue. Body image anxieties are a real concern. It is frightening to learn of statistics from Prof Rumsey saying that 11 year olds are wanting cosmetic procedures. It is sad to learn that poor body image is one of the 3 biggest concerns of our young people. I worry how this will affect my children, as I do not want them to grow up with poor body image, like I did, and like so many of my patients who see me. Dissatisfaction about how one looks can affect one’s confidence, and can negatively impact on every aspect of one’s life. I know first hand seeing how many people don’t want to do something because they fear rejection, failure or disapproval because they lack self-worth and often it is linked to how they negatively see themselves and their appearance. But do our young people feel this way because what some plastic surgeons have posted on their social media feed? Let’s be real here, people feel this way because they live in a world where beautiful, sexy, attractive is celebrated and promoted EVERYWHERE – on TV, in magazines, on billboards, in shop windows – not just on social media. And coupled with the harsh reality that the world is cruel. Even without magazines and TV influencing our perceptions, fleeting or deliberate comments from other children, teenagers and adults whether innocent and unintentional or not, can and do crush self esteem and confidence. Being teased or being told you are fat and ugly or have a big nose or whatever, is enough to play on our minds, and sadly, has longevity. And this type of bullying about one’s appearance begins from such a young age, and I don’t think that is because of social media. I see children worried about their prominent ears because the kids at school are mean. I see some adults who have little to no confidence and they attribute that to being bullied when younger because they were overweight. Where are we learning to be so mean? Whatever happened to the adage, if you don’t have anything nice to say, don’t say anything at all. I grew up before social media when we all had varying degrees of dissatisfaction with our bodies merely because I believed we lived in a time where the supermodels Cindy, Claudia, Kate and Kristy and magazines like Dolly, Cleo and Cosmopolitan portrayed the notion that being beautiful, skinny, perfect were what we aspired to be like and if we didn’t we felt awkward and unattractive. Perhaps we didn’t all follow these models and magazines, but the problem of not feeling good about how we looked is age old. Centuries before women were wearing corsets to cinch in their waist so making them attractive to potential suitors looking for fertility in a woman. Wonder if women back then had body image issues? They probably had some dissatisfaction if they didn’t meet society’s view of attractive then but perhaps they never articulated it. Or maybe people were more tolerant and embracing of all shapes and sizes and appearances back then? Scientific studies have shown that people are drawn to features of beauty instinctively – and that doesn’t require influences externally. There is an argument that it is innate to be drawn to certain physical characteristics, and so whilst social media can certainly influence trends, as Kylie Jenner has in my mind, redefined the image of beauty, there is so much more to this problem of poor body image than can be blamed on plastic surgeons and social media. Add the era of the internet and social media and now everything is available online. But I do not believe it is what is splashed everywhere that has killed our body confidence, in as much as the culture where its ok to troll others, speak unkind words, be overly critical, be cruel and pass judgement on others that in my mind has fuelled body image anxieties. I am not a psychologist or sociologist and don’t claim to have the answers to a complex and concerning problem, but I do believe the onus is on society at large to change how we treat others and to start from a young age to foster tolerance, acceptance and values of kindness. As a plastic surgeon, we have a responsibility to be a part of the solution. I do believe that we already help so many patients find their self worth, love themselves more, become less self conscious and live their best lives. But we also need to make sure that we don’t set unrealistic, unattainable expectations for our patients, sexualise or trivialise what we do or make people feel worse about themselves so we can offer solutions to their problems. As members of the Australian Society of Plastic surgeons and Australasian Society of Aesthetic Plastic Surgeons, we need to advance the specialty of plastic surgery so we can help more people. We should work together with body image specialists to find solutions to fostering healthy positive body image in society, and ensure our social media and marketing is ethical realistic, professional and honest. For some people, finding one’s self worth may require counselling. For others it might be about career advancement. And some it might mean lifestyle changes. However there will always be some women and men who want to address a physical concern that holds them back from feeling good about themselves and achieving what they want to. This is equally valid, and articles and opinions that criticise or mock those of us who want to invest in ourselves and improve our appearance, do the opposite of helping us. They actually fuel even more angst. I am not claiming that plastic surgery fixes low body image. I am not arguing that if you don’t like something about your physical appearance then fix it and your woes will be over. I am not advocating that we should all go and get a boob job because the ones we saw on social media are amazing and if we don’t we will feel less of a person. Sorry for the dramatic sarcastic tone, but I am sick and tired of shaming those who want to do something for themselves. So long as the individuals have realistic expectations and are doing it for themselves and for the right reasons, it isn’t right to criticise them, or judge them as being superficial, vain, weak or any other negative undertones that some people automatically associate with plastic surgery. We don’t need to agree with their choices but we should learn to respect their autonomy in the very least. It would be my hope that we learn to be encouraging and supportive of each other rather than criticise and shame each other’s choices. I for one see women and men of all different age groups and from all walks of life who simply want to improve an area of their skin, face or body that bothers them and affects their confidence, happiness and freedom to be their best selves. In no way are these patients coming in feeling crap about themselves because they aspire to be like influencers. The overwhelming majority of my patients don’t want to be someone else – they only want to be the best version of themselves whatever age or stage of life they are at. Some have insecurities from a young age when someone teased them and that has stuck with them through most of their life. Some have insecurities that have formed from growing up in this society that is skewed in favour of who and what is beautiful. Many are going through key stages in their life when they want to feel good about themselves. Mums who feel frumpy and unattractive after having kids want to address their post-pregnancy body. Men and women who have left long term relationships want to regain their self confidence that a breakup has taken its toll on. Some want to not look aged so they can hang onto their jobs. Whetever the reason so long as it is for the patient who has realistic expectations, plastic surgery can be highly transformative, not only physically but also in how it translates positively to every aspect of one’s life. At the end of the day, social media is not going away and we cannot stop people looking and following Instagram accounts of those they relate to or engage with and search for what fits with their belief systems. For the surgeons who are posting risqué pictures labelled as “soft porn”, they are likely attracting patients who identify with those desired outcomes, but I know that my patients or those who follow me share the same values that I do about empowering others to be their best and kind self. Each to their own so long as we are not breaching professional and ethical guidelines, and not lumped into one basket as being part of a serious complex problem. With further collaboration and research, we can all be part of a solution. Natural medicine industry welcomes Wentworth victory for Dr Kerryn Phelps 2018-10-25T01:05:32Z natural-medicine-industry-welcomes-wentworth-victory-for-dr-kerryn-phelps-1 Media Announcement: 25 October 2018 Natural medicine industry welcomes Wentworth victory for Dr Kerryn Phelps The largest Australian body representing 10,000 natural medicine practitioners, The Australian Traditional-Medicine Society (ATMS), today welcomed the historic victory for Dr Kerryn Phelps on securing her seat in Wentworth following the by-election. Dr Phelps recently spoke at a Candidates Forum in Wentworth hosted by ATMS with Angela Vithoulkhas, Licia Heath and Shayne Higson. The candidates presented their positions on natural medicine, healthcare and small business with strong support from all candidates for complementary medicine, recognising its current role as a viable option for the health and wellbeing of Australians. ATMS are thrilled that Dr Phelps has gained the seat and support her principles of continued coverage of natural therapies within health funds, despite changes being implemented by the current Government. Charles Wurf, CEO, ATMS stated, “The election of a candidate who is supportive of complementary medicine is critical in this current environment seeking to remove subsidies for private health insurance. Further changes forecast by the recently announced Labor policy would seek to remove the GST exemption for naturopathy and herbal medicine treatments.” “ATMS maintains that restricting the choice of natural medicine treatments available within health insurance will prove a false economy. Policies targeted at limiting effective, proven natural medicine treatments will lead to greater pressure on public health and public hospitals,” finished Mr Wurf. ATMS looks forward to working with Dr Phelps and like-minded, committed Parliamentarians to ensure natural medicine treatments are available as effective, viable choices within the Australian healthcare and wellness system. To see how ATMS are representing natural medicine professionals in Australia, visit: www.atms.com.au -Ends- NOTES TO EDITORS: Interviews with: Charles Wurf, CEO, ATMS, are available on request through the below contacts For media enquiries please contact: Debbie Bradley, Group Account Director, Zadro P: 02 9212 7867 | debbie@zadroagency.com.au Sinead Andrews, Account Coordinator, Zadro P: 02 9212 7867 | sinead@zadroagency.com.au Image: Charles Wurf, CEO, ATMS About the Australian Traditional-Medicine Society: The Australian Traditional-Medicine Society (ATMS) is the leader of the natural medicine industry, promoting and representing professional practitioners of natural medicine, who are encouraged to pursue the highest ideals of professionalism in their natural medicine practice and education. As Australia’s largest national professional association for natural medicine practitioners, ATMS is a multi-disciplinary association representing over 10,000 accredited practitioners throughout Australia. ATMS was founded in 1984 and is an incorporated not-for-profit company. In 2014 ATMS celebrated their 30th anniversary representing natural medicine practitioners in Australia. ATMS is governed by a Board of Directors, with specialised departments for Massage Therapy, Chinese Medicine, Homeopathy, Nutrition, Naturopathy and Western Herbal Medicine. www.atms.com.au CannaTech Sydney Speakers & Topics 2018-10-23T07:58:28Z cannatech-sydney-speakers-topics Media Advisory CannaTech Sydney Speakers & Topics Showcasing Medical Cannabis Industry Thought Leaders in Business, Medical Science & Technology at Australia’s First Medical Cannabis Summit October 28-30 Tel Aviv & Sydney, Oct. 23, 2018…CannaTech Sydney, Australia’s first ever Medical Cannabis Summit will highlight the biggest industry thought leaders known for their significant and ground-breaking contributions to the exploding global cannabis market in all fields. CannaTech covers a wide breadth of the most current industry topics agenda including presentations that cover Medical Science, Technology, Investment, International Regulation and more. Participants from around the world will gather at Doltone House, Darling Island. The summit will be preceded on October 28 by a special Cannabis Business Symposium. Journalists and photographers must register in advance! NOTE: There will be an on-site PRESS BRIEFING with CannaTech CEO Saul Kaye and several top international and Australian medical cannabis leaders on Monday, October 29, 11:15-11:45 am. Check with registration desk to confirm location. Following is a schedule of topics and speakers. Schedule subject to change. Sunday September 28, Business Symposium 14:00 - 14:30 Global Investment Trends and Forecasts: A Macro Assessment of the APAC Cannabis Market John Kagia/ Chief Knowledge Officer, Industry Analytics, New Frontier Data 14:30 - 15:00 Business Keynote: Making Sense of the Surging Global Cannabis Market Bruce Linton, Founder, Chairman and Co-CEO, Canopy Growth 15:00 - 15:30 How to Stay Competitive in an Expanding Global Market (the branding & marketing of medical cannabis) Brad Gobel, Director of Regulated Industries, Shopify Chris-Driessen, Partner; President, Organa Brands U.S. Jeremy-Heid, Co-Founder; President, Organa Brands International 15:30 - 16:00 Cannabusiness and Academia; Building for the Next Generation Nitin Mantri, Associate Professor, RMIT University Ron Lipsky, VP of Business Development, MGC Pharma 16:30 - 16:50 Going Global: Cannabis Business Opportunities in Latin America Alfredo Pascual, International Analyst, Marijuana Business Daily 16:50 - 17:00 Wholesale Cannabis Merchant Trading Platform Experience Saul Singer, Co-Founder & CEO of CMTREX 17:00 - 17:30 An In-depth Look at European Medical Cannabis 17:30 - 17:45 Constance Finley, Founder and CEO, Constance Therapeutics 17:45 - 18:15 Regulation’s Role in Global Partnerships & Cannabis Business Decisions Deepak Anand, VP, Business Development & Government Relations, Cannabis Compliance Inc. Pat McCutcheon, President and CEO, MediPharm Elaine Darby, Managing Director, AusCann Group Holdings Ltd Lynn Honderd, Co-Founder & CEO, Mary 18:15 - 18:45 Panel: Capital Market, The How and Why of Going Public Stephen Silver/ Managing Director, Hunter Capital Advisors Director, Capital Markets, TheraCann International Benchmark Corporation Jeremy Leibler, Partner, Arnold Bloch Leibler 18:45 - 19:00 Cannabis Investment Overview: Fear, Risk & How to Spot a Winner Brian Sheng, General Partner, Arcview Group 19:00 Closing Remarks Saul Kaye, CEO, Founder of iCAN: israel cannabis Monday, October 29, Summit Day 1 9:30 - 09:45 Lorne Gertner, Chairman & Co-Founder, Hiku Brands Company Ltd. Helen Kapalos, Chairperson, Victorian Multicultural Commission 09:45 - 10:00 The Ethnopharmacological History of Cannabis Justin Sinclair, Research Fellow, NICM 10:00 - 10:30 Policy & Regulation Panel: Getting on the Map in Global Medical Cannabis Policy and Next Steps for Australia Deepak Anand, VP, Business Development & Government Relations, Cannabis Compliance Inc. Mimi Busk Downey, Director of Regulatory Affairs, TheraCann International Benchmark Corporation Jonathan Zaid, Director of Advocacy and Corporate Social Responsibility, Aurora Carol Ireland, CEO and Managing Director, Epilepsy Action Australia 10:30 - 10:45 Humans of Medical Cannabis: The Road to 'Rylie's Law' Rylie Maedler, President & Founder, Rylie's Sunshine 10:45 - 11:15 Pharma 2.0 – Exploring the Development of Cannabis as Medicine Dr. Guy Chamberland, CSO & Regulatory Affairs, Tetra Bio-Pharma Constance Finley, Founder and CEO, Constance Therapeutics Sharlene Mavor, Medical Cannabis Research Australia (NFO) Dr. Melanie Kelly, Professor, Dalhousie University, Canada 11:45 - 12:00 Macro Trends on Global Cannabis Market (Including CBD) Giadha Decarcer, Founder & CEO, New Frontier Data 12:00 - 12:30 All Star Canadian Panel Vinay Tolia/ CEO, The Flowr Joshua Eades, Vice President, Chief Science Officer, Tilray Pradyum Sekar, CEO, Sail Cannabis 12:30 - 12:45 Beyond Physician and Patient Education Pradyum Sekar, CEO, Sail Cannabis 12:45 - 13:15 Global Insights Panel Cam Battley, Chief Corporate Officer, Aurora Cannabis Dr. Stewart Washer, VP Business Development, AusCann Ltd 13:15 - 13:30 Nutraceutical, Cannaceutical, and Pharmaceutical Stephane Redey, Scientific Industry Advisor, PhD, Creso Pharma 14:30 - 15:00 Effecting Change: The Advocates' Road to Compassionate Care Alice Oleary Randall, Medical Cannabis Pioneer, Editor-in-Chief, Mary's Lucy Haslam, Executive Director, Co-Founder, United in Compassion Lynn Honderd, Co-Founder & CEO, Mary 15:00 - 15:15 Cannabis & Cancer Research Prof. Marco Falasca, Professor, School of Pharmacy and Biomedical Sciences, Curtin University 15:15 - 15:30 The PELICAN study: Results and Implications for Policy Anastasia Suraev, Clinical Research Officer, Lambert Initiative for Cannabinoid Therapeutics 15:30 - 15:50 Australia’s First Producer Fleta Solomon, Managing Director, Little Green Pharma 15:45 - 16:05 Navigating Australia’s Cannabis Landscape Paul Mavor, Director, Health House and Medical Cannabis Research Australia 16:05 - 16:30 Using Microbes in Commercial Cannabis Cultivation Colin Bell, Chief Growth Officer, Growcentia Tuesday October 30, Summit Day 2 09:30 - 9:45 Next Gen Research: Clinical Research Programs Including Soon-to-be-Published Driving Data Prof Iain McGregor, Academic Director, Lambert Initiative for Cannabinoid Therapeutics 09:45 - 10:10 The Methodology of Studying and Doing Cannabis Research Dy. Ryan Vandrey, Associate Professor, Johns Hopkins University 10:10 - 10:35 The Regulation of the Cultivation and Manufacture of Medicinal Cannabis Products John Skerritt, Adjunct Prof FTSE FIPAA (Vic), Deputy Secretary, Department of Health, Australia 10:35 - 10:55 Chemotype Variance and the Relation to Clinical Health Outcomes Andrew Samann, CEO and Founder, Orion GMP Solutions 11:00 - 11:15 Potential of Cannabis-Based Medicines to Treat Psychiatric Illness and Improve Brain Health Dr. Katrina Green, Researcher, Lecturer, University of Wollongong 11:45 - 12:00 From Hemp to Cannabis: Around the World in Two Decades Paul Benhaim, Executive Director and CEO, Elixinol Global Limited 12:00 - 12:15 Expert Research on Cannabis for Epilepsy Prof. Uri Kramer, Scientific Advisor, MGC Pharma 12:15 - 12:30 Medical Research: Cancer and Full-spectrum Products, CBD:THC Synergy and Pain Jonathan Arnold, Associate Professor, Lambert Initiative for Cannabinoid Therapeutics 12:30 - 12:50 T​he Education and Administration of Medical Cannabis Treatment for Paediatric Care Naama Saban, RN BcS, Medifarm 12:50 - 13:10 Patient Centric Consumer Trends: Canadian Data Tells the Story Matei Olaru, CEO, Lift & Co. 13:10 - 13:30 Health, Science and Policy: A Patient First Agenda Dr. Mark Ware, Chief Medical Officer, Canopy Growth 14:30 - 14:50 The Importance of Maintaining an Honest Business Charles Feldmann, Head of International Cannabis Team, Cantafio Feldmann Nagel 14:50 - 15:10 Ensuring a Reliable, Economic, Practical and Safe Cannabis Regulatory Framework Chris Bolton, COO and Founder, TheraCann International Benchmark Corporation 15:10 - 15:30 Lessons from Canada: Medical Education and the Road Forward for Medical Cannabis in Australia Daniel Schecter, Co-founder & Medical Director of the Canadian Cannabinoid Medical Clinic 16:00 - 16:15 Science & Medicine: Next Steps in Cannabis Extraction Technology Pat-McCutcheon, President and CEO, MediPharm Labs 16:30 - 17:00 3 Under 30: The Future of Australian Medical Cannabis Adam Miller, Founder and CEO, BuddingTech Rhys Cohen/ Project Officer, Lambert Initiative for Cannabinoid Therapeutics Australian Media Contact for interviews, media enquiries and registration: Candice Meisels candice@candicepr.com To register and for further information contact Laura Kam, laura@kamgs.com, 972-54-806-8613.